Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) FCF Margin (2021 - 2025)

Mirum Pharmaceuticals has reported FCF Margin over the past 5 years, most recently at 3.67% for Q4 2025.

  • Quarterly results put FCF Margin at 3.67% for Q4 2025, up 879.0% from a year ago — trailing twelve months through Dec 2025 was 10.53% (up 776.0% YoY), and the annual figure for FY2025 was 10.53%, up 776.0%.
  • FCF Margin for Q4 2025 was 3.67% at Mirum Pharmaceuticals, down from 29.69% in the prior quarter.
  • Over the last five years, FCF Margin for MIRM hit a ceiling of 29.69% in Q3 2025 and a floor of 1056.41% in Q4 2021.
  • Median FCF Margin over the past 5 years was 38.18% (2023), compared with a mean of 152.83%.
  • Biggest five-year swings in FCF Margin: soared 93273bps in 2022 and later tumbled -2375bps in 2025.
  • Mirum Pharmaceuticals' FCF Margin stood at 1056.41% in 2021, then soared by 88bps to 123.67% in 2022, then surged by 81bps to 23.89% in 2023, then surged by 79bps to 5.12% in 2024, then skyrocketed by 172bps to 3.67% in 2025.
  • The last three reported values for FCF Margin were 3.67% (Q4 2025), 29.69% (Q3 2025), and 9.32% (Q2 2025) per Business Quant data.